Welcome to our dedicated page for Cingulate news (Ticker: CING), a resource for investors and traders seeking the latest updates and insights on Cingulate stock.
Cingulate Inc. (NASDAQ: CING) is a clinical-stage biopharmaceutical company dedicated to improving patient outcomes through its proprietary Precision Timed Release™ (PTR™) drug delivery platform. Headquartered in Kansas City, Kansas, the company is focused on developing next-generation pharmaceutical products that address conditions requiring burdensome daily dosing regimens and that often yield suboptimal treatment outcomes.
Cingulate’s lead candidates target Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety disorders, with a particular emphasis on their flagship product, CTx-1301. CTx-1301 utilizes dexmethylphenidate, a compound approved by the FDA, to provide a rapid onset and entire active-day efficacy through three precisely timed medication releases. This approach aims to eliminate the need for booster doses and improve overall patient compliance and satisfaction. The product has already demonstrated significant promise in Phase 3 trials, with impressive clinical effect sizes that suggest broad potential impact.
Another key product in the pipeline is CTx-2103, a novel extended-release formulation of buspirone designed for the treatment of anxiety. CTx-2103 leverages the PTR platform to deliver three timed doses in one tablet, potentially offering substantial benefits over current multi-dose regimens. This product is currently progressing through clinical trials, with positive feedback from the FDA on its regulatory pathway.
In recent months, Cingulate has achieved several milestones: they announced successful Phase 3 trial data for CTx-1301, closed a $4 million public offering, and converted $5.8 million of debt into equity. These financial maneuvers have strengthened their balance sheet, enabling continued investment in their clinical programs. Additionally, Cingulate recently welcomed new executive leadership and independent directors, further fortifying their capabilities as they navigate the complexities of drug development and commercialization.
Cingulate is committed to ongoing research and development, leveraging its PTR platform not only for ADHD and anxiety but also exploring other therapeutic areas. This innovative platform integrates an Erosion Barrier Layer (EBL), which controls the drug release at precise times without premature release, enhancing the effectiveness and convenience of treatment.
For more information, visit their official website at Cingulate.com.
Cingulate Inc. reported Q3 2024 financial results, highlighting a $19.5M increase in working capital. The company raised $12.5M in capital during Q3, extending cash runway into Q3 2025. Net loss decreased to $3.2M from $6.0M year-over-year, with R&D expenses dropping to $1.4M from $3.9M. The company secured European patents for its lead ADHD asset CTx-1301 in up to 30 territories and regained Nasdaq compliance. Cingulate remains on track for mid-2025 New Drug Application submission of CTx-1301.
Shane J. Schaffer, Chairman and CEO of Cingulate (NASDAQ: CING), appeared on the nationally syndicated Big Biz Show to discuss Cingulate's lead Phase 3 asset, CTx-1301, for the treatment of ADHD. Schaffer highlighted the company's Precision Timed Release™ (PTR™) drug delivery platform, which aims to advance next-generation pharmaceutical products. The discussion included plans for the commercialization of CTx-1301 and potential applications of PTR™ technology in other therapeutic areas. The Big Biz Show, hosted by Bob “Sully” Sullivan, is broadcast globally through partners like iHeart Radio and the American Forces Network.
Cingulate Inc. (NASDAQ: CING) has initiated its final FDA-required study for CTx-1301, a dexmethylphenidate-based treatment for ADHD. The food effect study is expected to yield results by the end of 2024. The company has also raised over $10 million in additional capital since mid-August 2024, with 58% coming from its at-the-market facility. This capital infusion strengthens Cingulate's balance sheet and supports the advancement of CTx-1301 towards NDA submission, targeted for mid-2025. Additionally, Cingulate has received notification from Nasdaq confirming its compliance with listing requirements, addressing previous concerns about potential delisting.
Cingulate (NASDAQ: CING) announced that Chairman and CEO Shane J. Schaffer, PharmD, will participate in a live Benzinga All Access event on August 28, 2024, at 10:30 a.m. CST. Schaffer will discuss the company's recent European patent, the ADHD market, and potential expansion of Cingulate’s Precision Timed Release™ (PTR™) drug delivery platform into other therapeutic areas. The event can be viewed live on Benzinga's YouTube channel and later on Cingulate's website.
Cingulate Inc. (NASDAQ:CING) has adjourned its Special Meeting of Stockholders due to insufficient quorum. The meeting is rescheduled for August 28, 2024, at 11:00 a.m. Central Time. The company's Board of Directors believes all proposals in the proxy statement are in the best interests of stockholders and recommends voting FOR all agenda items. The record date for the Special Meeting remains June 28, 2024. Stockholders can vote live by calling 1-800-652-8683 or online at www.envisionreports.com/CING-SP. Cingulate is a biopharmaceutical company using its Precision Timed Release™ (PTR™) drug delivery platform to develop next-generation pharmaceutical products.
Cingulate Inc. (NASDAQ: CING) has been granted a European patent for its lead asset CTx-1301 (dexmethylphenidate) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). The patent, issued on August 14, 2024, as EP Patent No. 3261625, covers up to 30 European territories, including the United Kingdom. This adds to Cingulate's existing patents in Australia, Canada, and Israel, with pending patents in Hong Kong, the Republic of Korea, and the United States.
The company views this as a significant milestone in its efforts to expand beyond the US market and make an impact on the growing ADHD markets in Europe and other territories. Cingulate utilizes its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to develop next-generation pharmaceutical products.
Cingulate Inc. (NASDAQ: CINGW) reported its Q2 2024 financial results and development updates. Key highlights include:
1. FDA clearance to file for marketing approval of CTx-1301 for ADHD, targeting NDA submission in 1H 2025.
2. Completion of registration batches for CTx-1301.
3. Ongoing licensing activity and positive payer study results for CTx-1301.
4. $1.6 million capital raised through warrant inducement.
5. One-for-twelve reverse stock split to maintain Nasdaq listing.
6. Q2 2024 financials: $0.4 million cash on hand, $3.1 million in stockholders' equity, and net loss of $3.2 million.
The company continues to progress towards CTx-1301's NDA submission while exploring licensing opportunities and addressing Nasdaq compliance requirements.
Cingulate announced the exercise of outstanding Series A and B warrants at a reduced price of $0.585 per share, generating gross proceeds of approximately $1.86 million. Originally issued in February 2023 with an exercise price of $2.00, the warrants allow the purchase of up to 3,187,500 shares of common stock. The transaction, facilitated by H.C. Wainwright & Co., is expected to close by July 1, 2024. In return, Cingulate will issue new Series C and D warrants to purchase up to 6,375,000 shares at the same reduced price, exercisable upon shareholder approval. Proceeds will fund R&D, commercialization of CTx-1301, and general corporate needs.
Cingulate, a biopharmaceutical company listed on NASDAQ under the symbol CING, will host a live event featuring CEO Shane J. Schaffer and ADHD expert Dr. Ann Childress. The event will be held on June 26, 2024, at 10:30 a.m. CST, and will be accessible via Benzinga’s YouTube channel and Cingulate’s website. During the event, the discussion will cover unmet needs in ADHD, results from Cingulate’s Phase 3 Fixed-Dose Study in pediatrics and adolescents, and potential expansion of the company's Precision Timed Release™ platform into other therapeutic areas. Dr. Schaffer will also provide a company overview.
Cingulate announced a significant achievement in the development of its ADHD drug, CTx-1301, by completing twelve required registration batches. This milestone meets the U.S. Food and Drug Administration (FDA) manufacturing requirements necessary for New Drug Application (NDA) submission. The company is using its Precision Timed Release™ (PTR™) technology to develop CTx-1301, intended to offer a reliable manufacturing process and acceptable shelf life. Cingulate plans to submit the NDA for CTx-1301 in the first half of 2025, marking a important step towards FDA marketing clearance.
FAQ
What is the current stock price of Cingulate (CING)?
What is the market cap of Cingulate (CING)?
What does Cingulate Inc. specialize in?
What is CTx-1301?
What recent financial achievements has Cingulate accomplished?
What is the Precision Timed Release™ (PTR™) platform?
How does CTx-2103 differ from other anxiety treatments?
What was the outcome of the Phase 3 trial for CTx-1301?
What is CTx-2103 being developed for?
What distinguishes Cingulate Inc. from other biopharmaceutical companies?
Where is Cingulate Inc. headquartered?
How can I learn more about Cingulate Inc.?
